Suppr超能文献

6-巯基嘌呤的生理药代动力学模型:探讨TPMT酶活性中基因多态性的作用。

Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.

作者信息

Ogungbenro Kayode, Aarons Leon

机构信息

Centre for Applied Pharmacokinetics Research, Manchester Pharmacy School, The University of Manchester, Oxford Road, Manchester, M13 9PT, United Kingdom.

出版信息

Br J Clin Pharmacol. 2015 Jul;80(1):86-100. doi: 10.1111/bcp.12588. Epub 2015 Jun 1.

Abstract

AIMS

To extend the physiologically based pharmacokinetic (PBPK) model developed for 6-mercaptopurine to account for intracellular metabolism and to explore the role of genetic polymorphism in the TPMT enzyme on the pharmacokinetics of 6-mercaptopurine.

METHODS

The developed PBPK model was extended for 6-mercaptopurine to account for intracellular metabolism and genetic polymorphism in TPMT activity. System and drug specific parameters were obtained from the literature or estimated using plasma or intracellular red blood cell concentrations of 6-mercaptopurine and its metabolites. Age-dependent changes in parameters were implemented for scaling, and variability was also introduced for simulation. The model was validated using published data.

RESULTS

The model was extended successfully. Parameter estimation and model predictions were satisfactory. Prediction of intracellular red blood cell concentrations of 6-thioguanine nucleotide for different TPMT phenotypes (in a clinical study that compared conventional and individualized dosing) showed results that were consistent with observed values and reported incidence of haematopoietic toxicity. Following conventional dosing, the predicted mean concentrations for homozygous and heterozygous variants, respectively, were about 10 times and two times the levels for wild-type. However, following individualized dosing, the mean concentration was around the same level for the three phenotypes despite different doses.

CONCLUSIONS

The developed PBPK model has been extended for 6-mercaptopurine and can be used to predict plasma 6-mercaptopurine and tissue concentration of 6-mercaptopurine, 6-thioguanine nucleotide and 6-methylmercaptopurine ribonucleotide in adults and children. Predictions of reported data from clinical studies showed satisfactory results. The model may help to improve 6-mercaptopurine dosing, achieve better clinical outcome and reduce toxicity.

摘要

目的

扩展为6-巯基嘌呤建立的基于生理的药代动力学(PBPK)模型,以纳入细胞内代谢,并探讨TPMT酶基因多态性对6-巯基嘌呤药代动力学的作用。

方法

对已建立的6-巯基嘌呤PBPK模型进行扩展,以纳入细胞内代谢和TPMT活性的基因多态性。系统和药物特异性参数从文献中获取,或使用6-巯基嘌呤及其代谢物的血浆或细胞内红细胞浓度进行估算。对参数进行年龄依赖性变化的缩放,并引入变异性进行模拟。使用已发表的数据对模型进行验证。

结果

模型成功扩展。参数估计和模型预测结果令人满意。对不同TPMT表型(在一项比较传统给药和个体化给药的临床研究中)的6-硫鸟嘌呤核苷酸细胞内红细胞浓度的预测结果与观察值以及报道的造血毒性发生率一致。按照传统给药方式,纯合子和杂合子变体的预测平均浓度分别约为野生型水平的10倍和2倍。然而,按照个体化给药方式,尽管剂量不同,但三种表型的平均浓度大致相同。

结论

已建立的PBPK模型已扩展用于6-巯基嘌呤,可用于预测成人和儿童血浆中6-巯基嘌呤以及6-巯基嘌呤、6-硫鸟嘌呤核苷酸和6-甲基巯基嘌呤核糖核苷酸的组织浓度。对临床研究报道数据的预测结果令人满意。该模型可能有助于改进6-巯基嘌呤的给药方案,取得更好的临床效果并降低毒性。

相似文献

引用本文的文献

5
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.影响抗癌药物药代动力学的基因分型
Clin Pharmacokinet. 2017 Apr;56(4):317-337. doi: 10.1007/s40262-016-0450-z.

本文引用的文献

4
Nomenclature for alleles of the thiopurine methyltransferase gene.硫嘌呤甲基转移酶基因等位基因命名法。
Pharmacogenet Genomics. 2013 Apr;23(4):242-8. doi: 10.1097/FPC.0b013e32835f1cc0.
9
Population-based mechanistic prediction of oral drug absorption.基于人群的口服药物吸收机制预测。
AAPS J. 2009 Jun;11(2):225-37. doi: 10.1208/s12248-009-9099-y. Epub 2009 Apr 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验